Background: 3-epi-25-hydroxyvitamin D 3 (3-epi-25OHD 3 ) interferes in most liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays for 25-hydroxyvitamin D (25OHD). The clinical significance of this is unclear, with concentrations from undetectable to 230 nmol/L reported. Many studies have quantified 3-epi-25OHD 3 based on 25OHD 3 calibrators or other indirect methods, and we speculated that this contributes to the observed variability in reported 3-epi-25OHD 3 concentrations. Methods: We compared continuous MS/MS infusions of 3-epi-25OHD 3 and 25OHD 3 solutions, spiked both analytes into the same serum matrix and analysed patient samples to assess the effect of three different quantitation methods on 3-epi-25OHD 3 concentration. Experiments were performed on an LC-MS/MS system using a phenyl column which does not resolve 3-epi-25OHD 3 , and a modified method utilizing a Zorbax SB-CN column that chromatographically resolves 3-epi-25OHD 3 from 25OHD 3 . Results: A greater 3-epi-25OHD 3 signal, compared with 25OHD 3 , was observed during equimolar post-column continuous infusion of analyte solutions, and following analysis of a serum pool spiked with both analytes. 3-epi-25OHD 3 signal enhancement was dependent on mobile phase composition. Compared with 3-epi-25OHD 3 calibrators, indirect quantitation methods resulted in up to 10 times as many samples having 3-epi-25OHD 3 concentrations ! 10 nmol/L, and an approximately fourfold increase in the maximum observed 3-epi-25OHD 3 concentration to 95 nmol/L. Conclusions: Enhanced 3-epi-25OHD 3 signal leads to overestimation of its concentrations in the indirect quantitation methods used in many previous studies. The enhanced signal may contribute to greater interference in some 25OHD LC-MS/MS assays than others. We highlight that equimolar responses cannot be assumed in LC-MS/MS systems, even if two molecules are structurally similar.
Introduction
There is interference from 3-epi-25-hydroxyvitamin D 3 (3-epi-25OHD 3 ) in most liquid chromatographytandem mass spectrometry (LC-MS/MS) 25hydroxyvitamin D (25OHD) assays. The clinical significance of this is unclear, with some studies reporting concentrations up to 230 nmol/L, 1 but others that 3-epi-25OHD 3 forms a minor proportion of total 25OHD 3 . 2, 3 This may reflect patient selection, since 3epi-25OHD 3 has been reported to be higher in infants than adults.
Some studies assume that equimolar 3-epi-25OHD 3 and 25OHD 3 produce equal signals in LC-MS/MS assays. 3-epi-25OHD 3 quantitation has been based on 25OHD 3 calibrators 1 or the difference in 25OHD 3 results between an assay which chromatographically separates the epimers and one that does not. 4 We noticed high 3-epi-25OHD 3 recovery in our routine 25OHD LC-MS/MS assay and speculated that 3-epi-25OHD 3 produces a greater signal than 25OHD 3 , enhancing interference in LC-MS/MS assays and overestimating 3-epi-25OHD 3 in assays lacking dedicated calibrators.
To investigate this, we spiked 3-epi-25OHD 3 and 25OHD 3 into serum, compared analyte infusions and analysed patient samples to assess different 3epi-25OHD 3 quantitation methods. We used two LC-MS/MS methods: our routine 'co-elution method' in which 25OHD 3 and 3-epi-25OHD 3 co-elute, and a 'resolving method' that chromatographically separates the epimers. Master solutions of 25OHD 3 and 3-epi-25OHD 3 at a concentration of 2.5 mmol/L were prepared in ethanol. The master solution was diluted 1/250 in ethanol to produce stock solutions of approximately 10 mmol/L. Concentrations of stock 3-epi-25OHD 3 and 25OHD 3 solutions were determined from their absorbances at 264 nm using a molar extinction coefficient " 0 ¼ 18,200 L mol À1 cm À1 , 2 a UVIKON spectrophotometer (NorthStar Scientific, Potton, UK) and quartz cuvettes. 25OHD-deficient human serum pools were prepared from surplus patient samples with total 25OHD < 10 nmol/L. Dedicated 3-epi-25OHD 3 calibrators were prepared in-house from 25OHD-deficient serum spiked with 3-epi-25OHD 3 . ChromSystems 3PLUS1 Õ Calibrator Set (Chromsystems, Munich, Germany) was used unmodified for 25OHD 3 calibration. ChromSystems MassCheck 25-hydroxyvitamin D 2 /D 3 serum controls (Level I and II) were used as quality control (QC) material for 25OHD 2 and 25OHD 3 . For 3-epi-25OHD 3 , QC material was prepared by spiking 3-epi-25OHD 3 into a human serum pool.
Materials and methods Materials

Specimen processing
Samples underwent semi-automated solid phase extraction (SPE) 5 and analysis on a Waters ACQUITY UPLC-TQD (Waters, Milford, MA, USA). Briefly, 150 mL sample was mixed with 20 mL 26,26,26,27,27,27-d 6 -25OHD 3 internal standard and proteins precipitated using ZnSO 4 and methanol. Following centrifugation, 600 mL of supernatant was transferred to a pre-conditioned Oasis HLB (30 mm) mElution plate (Waters, Milford, MA, USA). Sample cleanup on the mElution plate was via the use of aqueous methanol solutions. Analytes were eluted by 5% isopropanol/95% methanol into 96-well polypropylene plates (Waters, Milford, MA, USA). The 96-well plate was heat-sealed, vortexed and centrifuged before analysis.
MS parameters
Analytes underwent positive electrospray ionization and detection by multiple reaction monitoring. The 25OHD 3 and 3-epi-25OHD 3 response was the 401.3 > 159.1 peak area (collision energy 28 eV) relative to the d 6 -25OHD 3 internal standard 407.3 > 159.1 peak area (collision energy 28 eV). The 401.3 > 365.2 transition at a collision energy of 10 eV was used as a qualifier transition for both 25OHD 3 and 3-epi-25OHD 3 . For infusion experiments, we also monitored the 401.3 > 383.5 transition at a collision energy of 10 eV. The cone voltage was set at 22 V and the capillary voltage at 2.5 kV for all 25OHD 3 and 3-epi-25OHD 3 transitions.
Chromatography
Mobile phase A was water and mobile phase B was methanol, each supplemented with 2 mmol/L ammonium acetate and 0.1% (v/v) formic acid.
The co-elution method used a Waters ACQUITY UPLC BEH Phenyl column (1.7 mm, 2.1 Â 50 mm) (Waters, Milford, MA, USA) with mobile phase B increasing from 65% to 98% over 3.6 min at 0.45 ml/min followed by re-equilibration at 65% B. Analytes co-eluted at 2.7 min with a runtime of 5 min. The limit of quantitation was 7 nmol/L based on a signal-to-noise ratio of 10. Inter-batch % coefficient of variation (%CV) for 25OHD 3 was < 10% at 42 nmol/L and 97 nmol/L. Recoveries of 25OHD 3 spiked into serum were within 20% of target.
The resolving method used an Agilent Zorbax SB-CN column (1.8 mm, 2.1 Â 50 mm) (Agilent Technologies, Santa Clara, CA, USA) with mobile phase B held at 55% for 24 min at 0.4 mL/min to resolve 25OHD 3 (retention time 17.0 min) from 3-epi-25OHD 3 (retention time 19.6 min). The column was washed at 98% B and reequilibrated at 55% B. The limit of quantitation was 10 nmol/L based on a signal-to-noise ratio of 10. Interbatch %CVs were < 10% at 42 nmol/L and 91 nmol/L for 25OHD 3 , and 7.8% at 15 nmol/L and 11.7% at 50 nmol/L for 3-epi-25OHD 3 . Recoveries of 25OHD 3 and 3-epi-25OHD 3 spiked into serum were within 20% of target.
Spiking experiments
For spiking experiments, 25OHD-deficient serum was spiked with either 25OHD 3 or 3-epi-25OHD 3 . In the co-elution method, the response for both sets of samples was the combined (25OHD 3 þ 3-epi-25OHD 3 ) peak area divided by the d 6 -25OHD 3 internal standard peak area, as 25OHD 3 and 3-epi-25OHD 3 co-eluted. The concentration was calculated as the concentration measured in the base pool (9 nmol/L) plus the concentration of 25OHD 3 or 3-epi-25OHD 3 spiked in the sample.
In the resolving method, the response for 25OHD 3 spiked serum was the 25OHD 3 peak area divided by the d 6 -25OHD 3 internal standard peak area, and the concentration was the 25OHD 3 concentration measured in the base pool (10 nmol/L), plus the concentration of 25OHD 3 spiked in the sample. The response for 3-epi-25OHD 3 was the 3-epi-25OHD 3 peak area divided by the d 6 -25OHD 3 internal standard peak area, and the concentration was the 3-epi-25OHD 3 concentration spiked (3-epi-25OHD 3 was not detected in the base pool). 
Infusion experiments
For infusion experiments, 1 mmol/L 3-epi-25OHD 3 and 25OHD 3 solutions were prepared by dilution of stock solutions with 80:20 methanol:isopropanol and infused post-column with mobile phase.
Analysis of patients' samples
Samples were analysed from 341 patients, of which 211 were randomly selected and 130 were chosen from children (<18 years) or because they had 25OHD concentrations > 50 nmol/L. The study included 227 female and 113 male patients (gender unknown for one subject). Seven subjects were aged < 1 year (youngest 8 days), 87 aged 1-18 years, and 247 aged > 18 years (oldest 88 years). Quantification of 3-epi-25OHD 3 was performed:
1. using dedicated calibrators in the resolving method; 2. using 25OHD 3 calibrators in the resolving method; 3. as the difference between 25OHD 3 results in the co-elution and resolving methods.
Results
Equimolar 3-epi-25OHD 3 gave a greater response than 25OHD 3 when the same serum pool was spiked with either compound, being approximately 60% greater in the co-elution method, and 20% greater in the resolving method ( Figure 1 ). This was also true when analytes were quantified using the 401.3 > 365.2 transition (data not shown).
When infusing equimolar solutions into the MS, the 3-epi-25OHD 3 signal was greater than 25OHD 3 for the 401.3 > 159.1 transition (Figure 2 ). The epimer signal enhancement during analyte elution ($2.7 min) in the co-elution method (Figure 2(a) ) was double the signal enhancement seen in the isocratic resolving method (Figure 2(b) ). This was verified on a second independently prepared set of infusion solutions. Increasing methanol concentrations increased the difference between epimer signals (Figure 2(c) ). The same pattern was observed when infusions were monitored with either 401.3 > 365.2 (Figure 3 When quantified using dedicated calibrators, 3epi-25OHD 3 was present at between 10 and 22 nmol/L in five of 341 patient samples (Table 1 ). Using 25OHD 3 calibrators, the number of samples which had 3epi-25OHD 3 concentrations ! 10 nmol/L was increased two to threefold. Quantitation of 3-epi-25OHD 3 as the difference in 25OHD 3 between co-elution and resolving methods resulted in 10 times as many samples with 3epi-25OHD 3 ! 10 nmol/L, and an approximately fourfold increase in the maximum concentration to 95 nmol/L.
Discussion
We demonstrated enhanced 3-epi-25OHD 3 signal relative to equimolar 25OHD 3 during infusions and in spiked human serum. Enhanced signal caused overestimation of 3-epi-25OHD 3 concentrations when quantified using 25OHD 3 calibrators or as the difference in 25OHD 3 results between an assay that chromatographically separates the epimers and a method in which they co-elute.
It is unclear if enhanced 3-epi-25OHD 3 signal occurs in all LC-MS/MS systems. In a Vitamin D external quality assessment scheme (DEQAS), 3-epi-25OHD 3 interference studies (sample 405) showed an average cross-reactivity > 100% in LC-MS/MS methods. 6 The wide spread of LC-MS/MS results for this sample (%CV 23.5% vs. %CV 10.8% in the base sample) suggest variable 3-epi-25OHD 3 interference, possibly due to variable enhancement of 3-epi-25OHD 3 signal. Our analyte infusion studies showed signal enhancement for In both infusion and spiking experiments, the 3-epi-25OHD 3 signal enhancement was two to threefold greater in the co-elution than in the resolving method. Infusion experiments showed increasing signal enhancement at higher methanol concentrations; since 3-epi-25OHD 3 elutes at approximately 55% methanol in the resolving method and approximately 80% in the co-elution method, this may explain the greater signal enhancement in the latter. This dependence of signal enhancement on mobile phase composition may also contribute to the variable 3-epi-25OHD 3 interference between DEQAS participants in the interference studies noted above.
As the molar extinction coefficient for 3-epi-25OHD 3 is unknown, we used the same value as for 25OHD 3 to assign concentration, an approach used by others. 2 The inversion of stereochemistry at C3 is chemically distant from the triene chromophore, but differences in UV absorption cannot be excluded. However, we would not expect the difference in UV absorption to exceed the < 10% difference between 25OHD 3 (" 0 ¼ 18,200 L mol À1 cm À1 ) and 25OHD 2 (" 0 ¼ 19,400 L mol À1 cm À1 ) absorbance. Any difference in 3-epi-25OHD 3 and 25OHD 3 concentrations due to inaccurate assignments of molar extinction coefficients cannot explain the different magnitudes of signal enhancement between the two methods, the variation of signal enhancement with methanol concentrations or the over-recovery of 3-epi-25OHD 3 by LC-MS/MS users in a DEQAS 3-epi-25OHD 3 interference experiment. 6 Signal enhancement could occur due to extraction, ionization or fragmentation differences. As 3epi-25OHD 3 enhancement was observed during infusion experiments, extraction differences alone cannot be responsible. Since 3-epi-25OHD 3 and 25OHD 3 fragment similarly 8 and enhancement was observed for Ion suppressing substances could cause ionization differences in the resolving method if co-eluting with either analyte. However, no ion suppression was observed when analytes were co-infused with extracted serum during validation of the resolving method (data not shown), and infusion experiments show a consistently greater signal for 3-epi-25OHD 3 . Ion suppression is an unsatisfactory explanation in the co-elution method, where analytes would be subjected to similar ion suppression. We suggest that intrinsic differences between 3-epi-25OHD 3 and 25OHD 3 ionization exist, modulated by factors such as mobile phase composition.
In some cases, quantitation of 3-epi-25OHD 3 as the difference between 25OHD 3 concentrations in the coelution and resolving methods caused concentrations to increase four to fivefold compared with using dedicated calibrators. This cannot be explained solely by 3epi-25OHD 3 signal enhancement and could be due to other unidentified 25OHD 3 isobars.
Studies using dedicated 3-epi-25OHD 3 calibrators reported low concentrations of this analyte, forming a minor fraction of total 25OHD 3 , 2,3 whereas studies using indirect quantitation have reported higher results, with 3-epi-25OHD 3 in excess of 25OHD 3 in some individuals. 1, 4 Our results suggest that previously unrecognized differences in epimer ionization contribute to these discrepancies.
Accurate 3-epi-25OHD 3 measurement could also be affected by the lack of an isotope labeled 3-epi-25OHD 3 internal standard, which was unavailable during this study. In the resolving method, we used d 6 -25OHD 3 as internal standard for 3-epi-25OHD 3 and ensured that chromatography was sufficient to resolve ion suppressing substances.
The resolving method was developed to investigate 3epi-25OHD 3 interference in 25OHD analysis. The limit of detection of the method is higher than has been reported for other 3-epi-25OHD 3 assays. 2,3 However, our intention was not to develop a reference method for 3-epi-25OHD 3 but rather to demonstrate the effect that different quantitation models can have on 3epi-25OHD 3 quantitation. Similarly, the resolving method's extended runtime precludes routine use. However, 3-epi-25OHD 3 can be partially separated within 6.5 min. 9 We advise that LC-MS/MS users quantitatively assess 3-epi-25OHD 3 interference in their 25OHD assays and consider modifications to minimize interference. We also advise using 3-epi-25OHD 3 calibrators if direct quantitation of this isomer is required.
Non-stoichiometric cross-reactivity is a familiar concept in immunoassays; we highlight that equimolar responses cannot be assumed in LC-MS/MS systems, even if two molecules are structurally similar. Furthermore, as cross-reactivity can differ between immunoassays due to differing antibody specificity and/or assay configuration, variable ionization is a possible mechanism for differing degrees of interference between LC-MS/MS assays. Using 3-epi-25OHD 3 calibrators in the resolving method, using 25OHD 3 calibrators in the resolving method, and as the difference between 25OHD 3 results in the co-elution and resolving methods.
